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Huntington's disease is triggered by misfolding of fragments of mutant forms of the huntingtin protein (mHTT)
with aberrant polyglutamine expansions. The C4 single-chain Fv antibody (scFv) binds to the first 17 residues
of huntingtin [HTT(1-17)] and generates substantial protection against multiple phenotypic pathologies in situ
and in vivo. We show in this paper that C4 scFv inhibits amyloid formation by exon1 fragments of huntingtin
in vitro and elucidate the structural basis for this inhibition and protection by determining the crystal structure of
the complex of C4 scFv and HTT(1-17). The peptide binds with residues 3–11 forming an amphipathic helix
that makes contact with the antibody fragment in such a way that the hydrophobic face of this helix is shielded
from the solvent. Residues 12–17 of the peptide are in an extended conformation and interact with the same
region of another C4 scFv:HTT(1-17) complex in the asymmetric unit, resulting in a β-sheet interface within a
dimeric C4 scFv:HTT(1-17) complex. The nature of this scFv–peptide complex was further explored in
solution by high-resolution NMR and physicochemical analysis of species in solution. The results provide
insights into the manner in which C4 scFv inhibits the aggregation of HTT, and hence into its therapeutic
potential, and suggests a structural basis for the initial interactions that underlie the formation of
disease-associated amyloid fibrils by HTT.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Huntington's disease (HD) is the most prevalent of
a set of human neurodegenerative disorders linked
to expansion of polyglutamine (polyQ) tracts in
specific proteins [1,2]. The full-length protein asso-
ciated with HD, huntingtin (HTT), is found predom-
inantly in the cytosol. In the disease state, however,
N-terminal proteolytic fragments of mutant forms of
HTT (mHTT), which are characterized by aberrant
expansions of the wild-type polyQ tract of N36
residues, are found to accumulate as insolubleAuthors. Published by Elsevier Ltd. T
rg/licenses/by/4.0/).inclusions in cellular nuclei [3–6]. The proteolytic
fragment of mHTT that is found to bemost pathogenic
is the exon1 fragment of mHTT, and overexpression
of this fragment has been shown to be sufficient to
produce rapid HD pathology in cells and organotypic
tissue, as well as in yeast and animal models,
including Drosophila and mouse models [7–10].
The sequence of the HTT-exon1 fragment can be
divided into three regions: a 17-residue N-terminal
region [HTT(1-17)], immediately followed by the
polyQ tract of variable length and a proline-rich
region at the C-terminal end of the peptide [11]. Thehis is an open access article under the CC BY license
J Mol Biol (2015) 427, 2166–2178
2167Structure of a Single-Chain Fv Bound to HuntingtinHTT(1-17) region is highly conserved, has a high
propensity to adopt an amphipathic α-helical struc-
ture and has been shown to be involved in
membrane binding, sub-cellular localization, aggre-
gation and toxicity [12–20]. The C- and N-terminal
polyQ flanking sequences have opposite effects on
the aggregation kinetics of mHTT-exon1 fragments
when studied in vitro. Whereas the proline-rich
sequence at the C-terminal end of the protein has
a strong inhibitory effect on the aggregation of
mHTT-exon1 fragments, the HTT(1-17) region en-
hances the aggregation kinetics of these fragments
and of designed synthetic fusions of HTT(1-17) and
other polyQ peptides by several orders of magnitude
[21,22]. It has been suggested that the HTT(1-17)
and the proline-rich regions interact with each other
in the full-length protein and also that expansion of
the polyQ chain disrupts this interaction, leading to a
higher propensity for mHTT to aggregate [14].
A naïve human single-chain Fv antibody (scFv)
phage-display library screened against HTT(1-17)
was used to select the C4 scFv for use as an
intrabody (a scFv antibody fragment that is engi-
neered to be expressed within diseased cells). The
C4 scFv intrabody can very effectively counteract
the length-dependent polyglutamine expansion that
induces pathologic HTT aggregation in cell culture,
Drosophila, and mouse models of HD [23–25]. In this
manuscript, we describe the effects of C4 scFv on
the in vitro aggregation properties of mHTT protein
fragments and report the crystal structure of the
antibody fragment in complex with the 17-residue
peptide at 2.5 Å resolution, as well as the charac-
teristics of the binding of these two species in
solution using NMR spectroscopy.Fig. 1. C4 scFv specifically inhibits the aggregation of the ex
of samples of MBP-HTT-Ex1-Q46 after digestion with TEV for
subsequently incubated for 70 h (total time = 76 h) with C4 sc
(lane 5) or with the negative control antibody fragment scFvR1
are indicated on the right-hand side and lane 2 shows protein m
95, 130 and 250 kDa). Bottom panel: Western blot analysis of
1C2 anti-polyQ as the primary antibody [61]. (b) Densitometric
presence of C4 scFv (C4) and QBP1 or in the absence of added
(a). The solubility of HTT-Ex1-Q46 following 6 h of digestion
deviations calculated from two independent experiments are sResults
Inhibition of the in vitro aggregation of
mHTT-exon1 huntingtin fragments by the
intrabody C4 scFv
The antibody fragment C4 scFv has been shown
to inhibit strongly the formation of intracellular
inclusions of mHTT-exon1 fragments of huntingtin
in cellular and animal models of HD [23–25]. These
experiments were, however, conducted in complex
cellular environments, and so we investigated the in
vitro ability of the isolated C4 scFv protein to inhibit
the aggregation of mHTT-exon1 protein fragments.
Here, we used purified HTT-exon1 peptides that
contain 46 glutamine residues in their polyQ tract
(HTT-Ex1-Q46), which were expressed as recombi-
nant and soluble maltose binding protein (MBP)
fusion proteins in Escherichia coli [26]. Proteolytic
removal of this MBP solubilization tag using tobacco
etch virus (TEV) protease initiated the aggregation of
the HTT-Ex1-Q46 peptide, which was essentially
complete after ~76 h (Fig. 1).
When C4 scFv was added after the proteolytic
cleavage of MBP, effectively all of the HTT-Ex1-Q46
peptide remained soluble for incubation times of at
least 76 h, an effect similar to that of the well-known
peptide inhibitor of polyQ aggregation, polygluta-
mine binding peptide 1, QBP1 [27], which we
included in our experimental strategy as a positive
control (Fig. 1). To evaluate the specificity of the
inhibition of mHTT by C4 scFv, we incorporated a
gankyrin-specific scFv, scFvR19 [28], into the
experimental design. As expected, this antibodyon1 of mHTT in vitro. (a) Top panel: Coomassie-stained gel
6 h (lane 1) and a 6-h TEV digest of MBP-HTT-Ex1-Q46
Fv (lane 3), with no added compound (lane 4), with QBP1
9 (lane 6). The positions of the different proteins on the gel
olecular weight markers (from bottom to top: 28, 36, 55, 72,
the soluble fraction of HTT-Ex1-Q46 for each sample using
based quantification of the solubility of HTT-Ex1-Q46 in the
compound (/), following the same incubation protocol as in
is used as 100% solubility reference point. The standard
hown as error bars.
2168 Structure of a Single-Chain Fv Bound to Huntingtinfragment had no detectable effect on the extent of
aggregation by HTT-Ex1-Q46 when it was added at
the beginning of the aggregation reaction (Fig. 1).
Crystal structure of the C4
scFv:HTT(1-17) complex
We investigated the nature of the interaction of the
C4 scFv intrabody with the HTT(1-17) peptide at
atomic resolution by co-crystallizing the two species.
The complex was found to crystallize under a range
of conditions involving mixtures of polyethylene
glycol 4000, ammonium sulfate and acetate buffer,
at pH values close to 4.6. Several crystals were
tested for their diffraction properties and we studied
in detail the one showing the highest-quality data, for
which the low-temperature X-ray diffraction data
extended to 2.5 Å. Crystallographic analysis of the
diffraction data further revealed that the crystal
belonged to space groupC2, with unit cell dimensions
a = 151.3 Å, b = 35.9 Å, c = 110.95 Å, α = 90.0°,
β = 120.72° and γ = 90.0° (Table 1). We solved the
structure by using the maximum likelihood molecular
replacement technique and a combination of auto-
mated andmanual building and refinement steps. TheTable 1. Crystallography data and refinement statistics
Data collection
C4 scFv:HTT(1-17)
Space group C2
Cell dimensions
a, b, c (Å) 151.31, 35.93, 110.95
α, β, γ (°) 90.00, 120.72, 90.00
Resolution range (Å)a 44.24–2.50 (2.59–2.50)
Rmerge
a 0.0305 (0.2542)
〈I/σ(I)〉a 14.45 (2.62)
Completeness (%)a 99.02 (96.97)
Redundancya 4.6
Reflections measureda 35,795 (3484)
Unique reflectionsa 18,104 (1763)
Wilson B-factor (Å2) 44.87
Refinement
Resolution range (Å) 44.24–2.50
Reflections (total) 18,092
Reflections (Rfree) 907
Rwork/Rfree (%) 18.2/22.6
NCS groups 3
TLS groups 46
No. of non-hydrogen protein atoms 3554
No. of ligand atoms 20
No. of water molecules 32
Average B-factor (Å2) 53.60
RMS deviations
Bonds (Å) 0.003
Angles (°) 0.72
Ramachandran plot
Ramachandran favored (%) 96
a Numbers in brackets represent the highest-resolution shell.structure was refined to giveR and Rfree factors equal
to 18.2% and 22.6%, respectively (Table 1).
The residues of the C4 scFv molecules were
found to give rise to clearly defined regions of
electron density, including those residues corre-
sponding to the antigen binding loops L1–L3 and
H1–H3. The loops L1 and L2 of the VL (λ) domain of
C4 scFv were found to adopt conformations
consistent with the canonical structure classes Lλ1
and Lλ2, respectively, and the conformation of the
L3 loop could be classified as canonical structure
class Lλ3 1B [29]. The CDR-H1 and CDR-H2 loops
[complementarity-determining region (CDR)] could
be classified as canonical class 1 and canonical
class 3, respectively [29]. We could also observe
clear electron density for the atoms of the bound
HTT(1-17) peptide, which enabled a structural
model to be constructed (Fig. S1). We found that
the asymmetric unit was in fact composed of two C4
scFv:HTT(1-17) complexes that were bound to
each other through interactions between residues
of the peptide ligand, resulting in a dimer of C4
scFv:HTT(1-17) complexes related to each other by
a 2-fold non-crystallographic symmetry axis
(Fig. 2).
Detailed analysis of a single C4 scFv:HTT(1-17)
complex shows that the residues 3–11 of the bound
HTT(1-17) peptide fold into a right-handed α-helix,
while residues 12–17 of HTT(1-17) are in an extended
conformation, of which residues 12–15 adopt a
β-sheet structure (Figs. 3 and 4). The C4 scFv binding
to the peptide involves the side chain of Phe11 of
HTT(1-17) being located in a hydrophobic pocket
formed by the side chains of Trp47VH, Val50VH,
Pro225VL, Arg100VH and Phe102VH and the Cβ
atoms of residues Ser33VH and Ser35VH (Fig. 3).
The side chain of Leu7HTT makes contact with the
aromatic ring of Tyr59VH and Phe220VL and interacts
with the backbone atoms of several residues of the
third antigen binding loop (CDR-L3) of the VL domain,
namely, Asn222VL, Ser223VL and Gly224VL. The
Oγ atom of Ser33VH is hydrogen bonded to the
carbonyl oxygen of Phe11HTT, and the carbonyl
oxygen of Glu12HTT is hydrogen bonded to the NH
backbone amide of Tyr53VH. Ser13HTT forms hydro-
gen bonds with Asp99VH and Ser33VH, and there is a
main-chain hydrogen bond between the NH group of
Leu14HTT and the CO group of Ser31VH. Leu14HTT
also makes close contacts with the aromatic ring of
Tyr53VH (Fig. 3).
Of particular interest, however, is that the C4 scFv:
HTT(1-17) complexes are bound together in pairs
through interactions between residues 11 and 17 of
both HTT(1-17) peptides. Indeed, the two peptide
molecules associate to form an antiparallel β-sheet
structure, involving an extensive network of hydro-
gen bonds between the main-chain atoms of
residues 14–16 of each molecule (Fig. 4a), which
is further stabilized through two C4 scFv-mediated
Fig. 2. Crystal structure of the C4 scFv:HTT(1-17) complex. Ribbon diagram of the two C4 scFv:HTT(1-17) complexes
in the asymmetric unit. The VH and VL domains of the C4 scFv are shown in green and blue, respectively (labeled
“VH” and “VL” at the C-terminal side of the respective domain). The HTT(1-17) peptides are shown in red and purple and
the N- and C-termini of the peptides are labeled with “N” and “C”. The top and the bottom view are related to each other by a
90° rotation along the x-axis.
2169Structure of a Single-Chain Fv Bound to HuntingtinhydrogenbondsbetweenSer31VH and Leu14HTT and
between Tyr53VH and Glu12HTT, resulting in an
extended β-sheet (Fig. 4a). The amide and carbonyl
groups of Ser13HTT are hydrogen bonded to the
carbonyl and amide groups of Lys15HTT, respectively,
which in addition allows the Oγ of Ser16HTT to make a
hydrogen bond with the carbonyl group of Met8HTT of
the adjacent peptide molecule (Fig. 4b). The dimeric
arrangement of both peptides is possibly also further
stabilized by the burial of the side chain ofPhe17HTT in
the hydrophobic cavity formed by the aromatic side
chains of Phe11HTT, Phe220VL and Tyr161VL and
by the aliphatic atoms of the side chain Arg100VH
(Fig. 4b). The side-chain atoms of both F17HTT and
F220VL do not have well-defined positions in the
electron density maps (Fig. 4b), suggesting that these
residues are partially disordered and have a higherdegree of conformational flexibility compared to the
remainder of the structure.
To evaluate the significance and the possible
biological relevance of the various interfaces found
within the crystal structure, we performed PISA
(Proteins, Interfaces, Structures and Assemblies)
analysis (Table 2 and Table S1) [30]. This approach
provides estimates for a number of parameters
defining each interface from the details of the
structure, including the free energy of formation,
the gain in solvation energy, the total and buried
areas of the interface, the number of hydrogen
bonds and salt bridges across the interface and the
hydrophobic complementarity [31]. Based on this
analysis, potentially biologically relevant elements
of quaternary structure can be distinguished from
simple crystallographic contacts.
Fig. 3. Detailed view of the binding interaction of a single C4 scFv molecule in complex with a single HTT(1-17) peptide.
The VH and VL domains of the C4 scFv are shown in green and blue, respectively; the HTT(1-17) peptide is shown in red.
The side chains of those residues of the HTT(1-17) peptide and of C4 scFv that have atoms that lie within 5 Å of each other
are represented as sticks and are labeled. The hydrogen bonds made by residues 11, 12 and 13 of HTT(1-17), with
residues of C4 scFv are shown as dotted lines.
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energies indicate that the interaction between the
two C4 scFv:HTT(1-17) complexes in the asymmet-
ric unit is likely to have a high stability in solution and
suggests that the [C4 scFv:HTT(1-17)]2 dimer is the
most significant assembly of the protein chains
(Table 2). Table 2 further indicates that the interface
between the peptide moieties in the C4 scFv:
HTT(1-17) dimer, in particular, is expected to have
the highest stability and the highest energetic cost
for its dissociation of all the interfaces found in this
assembly state.
The nature of the C4 scFv:HTT(1-17) complex
in solution
To probe the interaction of the C4 scFv with
HTT(1-17) in solution, we performed gel-filtration
chromatography, analytical centrifugation and mass
spectrometry on samples containing either the
intrabody or the peptide separately, or samples
containing various amounts of both molecules (Fig.
S2). The results of these experiments confirmed that
both free C4 scFv and C4 scFv bound to the
HTT(1-17) peptide are predominantly monomeric in
solution (Fig. S2).
Using 15N-1H heteronuclear single quantum co-
herence (HSQC) NMR spectroscopy, we could
probe in detail the binding of the HTT(1-17) peptide
in solution by measuring the perturbations of the
backbone amide resonances of the antibody
fragment that resulted from the presence of
HTT(1-17).A series of standard three-dimensional triple-
resonance NMR techniques enabled us to assign
201 and 208 of the 235 non-proline C4 scFv residues
for the free and bound states of C4 scFv, respec-
tively. We could not observe any peaks correspond-
ing to the six histidine residue purification tag at the
C-terminus of the C4 scFv and we could not assign 8
residues of the 12-residue Gly-Ser linker that
connects the VH with the VL domain due to spectral
overlap. Other “missing” resonances for both the free
spectrum and the bound spectrum include G237,
T203, I204, I177, Y178, G157, T152, Y101, Y95,
V50, I51, V37, T28, G16 and Q5. In the free
spectrum of the C4 scFv, the resonances corre-
sponding to residues R100, D99, A97, C96, A61,
Y60, Y59 and S52 could not be observed due to line
broadening.
An overlay of the HSQC spectra measured for C4
scFv in its free state and in the presence of a
saturating concentration of HTT(1-17) shows that
many of the backbone amide resonances in the
spectrum of free C4 scFv have shifted to new
positions in the spectrum of the bound state (Fig. 5a),
indicating that these residues are in close proximity
to the site of peptide binding. In addition, the
resonances of residues R100, D99, A97, C96,
A61, Y60, Y59 and S52, for which the intensities of
the signals in the free spectrum were below the noise
level and that were therefore not assigned, could be
detected and assigned in the bound spectrum.
These residues are located in, respectively, the
CDR-H2 and CDR-H3 regions of the C4 scFv and
make contact with the HTT(1-17). The results
Fig. 4. Detailed view of the interaction between the two peptides in the dimeric C4 scFv:HTT(1-17) complex. (a) General
view and (b) stereo representation of the detailed view of the interaction of the side chain of F17 of HTT(1-17) with residues
of the other HTT(1-17) peptide:C4 scFv complex in the asymmetric unit. The C atoms of the peptides bound to the different
C4 scFv molecules are colored purple and red, respectively, and O and N atoms are colored red (pink) and blue,
respectively. Residues originating from the antibody fragments are colorcoded as follows: C, cyan (VL) or green (VH); O,
red; N, blue. Interacting residues are labeled and hydrogen bonds are indicated using gray dotted lines. 2Fo − Fc electron
density maps (at 1.2σ) of the residues in this region are represented as a light-blue mesh.
2171Structure of a Single-Chain Fv Bound to Huntingtinsuggest that these residues becomemore ordered in
the bound state compared to the free state of the
antibody fragment.
The residues whose resonances have the largest
chemical shift perturbations coincide with the resi-
dues that are observed in the crystal structure to be
involved in contacts with residues of the peptide
(Fig. 5b and c). Small chemical shift perturbations
are also observed for those residues, includingPhe220VL and Tyr161VL of C4 scFv, that are in
contact with Lys15HTT, Ser16HTT and Phe17HTT in
the crystal structure, indicating that such contacts
might also be formed in solution (Fig. 5b and c).
There is no evidence, however, for line broadening
associated with the formation of a higher-molecular-
weight species corresponding to a dimeric arrange-
ment of two C4 scFv:HTT(1-17) complexes. These
observed shifts might therefore be explained by
Table 2. PISA analysis of the assemblies in the crystal structure of C4 scFv:HTT(1-17) that are expected to be stable in
solution
Compositiona ASAb (103 Å2) ΔASAc (103 Å2) ΔGint
d (kcal/mol) ΔGdiss
e
(kcal/mol)
Dissociation patternf
VL/VH-HTT-HTT-VL/VH 20.3 6.8 −50.1 4.5 VL/VH-HTT + VL/VH-HTT
VL/VH -HTT 11.0 g 2.5g −18.0g 3.9g VL/VH + HTT
VH-HTT-HTT-VH 12.7 3.1 −21.3 0.2 VH-HTT + HTT-VH
VH-HTT 7.0g 0.89g −6.5g 2.5g VH + HTT
HTT-HTT 2.7 0.79 −5.6 1.1 HTT + HTT
a VL/VH: the variable domains of the light and heavy chains of C4 scFv; HTT: HTT(1-17).
b Total solvent-accessible surface area of the assembly.
c Total solvent-accessible surface area of the units of assembly buried upon formation of the assembly.
d The solvation free energy gain upon formation of the assembly, in kilocalories per mole.
e The free energy of assembly dissociation, in kilocalories per mole.
f Dissociation pattern for the calculated free energy of dissociation.
g Average value for both assemblies in the asymmetric unit.
2172 Structure of a Single-Chain Fv Bound to Huntingtincontacts between residues of the same peptide
and the resulting contacts of these residues with
the C4 scFv antibody fragment or by secondary
perturbations of a stronger interaction located further
away in the binding interface. As a preliminary
evaluation of the contributions of residues Lys15HTT,
Ser16HTT and Phe17HTT, we performed isothermal
calorimetry measurements using the wild-type pep-
tide HTT(1-17) and the truncated peptides HTT(1-16),
HTT(1-15) and HTT(1-14) (Fig. S3). Our observations
show that the shorter peptides have slightly lower
affinities, with the HTT(1-14) peptide showing a
10-fold decrease in binding affinity compared to
HTT(1-17). Although this observation argues that
Lys15HTT, Ser16HTT and Phe17HTT contribute to the
binding of C4 scFv, the interaction appears to beweak
and is probably highly dynamic.Discussion
C4 scFv inhibition of mHTT-exon1 aggregation
In the present study, we have found that C4 scFv
inhibits the aggregation of HTT-Ex1-Q72 peptides
in vitro (Fig. 1), a result that is consistent with
observations from in situ and in vivo studies [24,25].
The crystal structure of the intrabody C4 scFv in
complex with the HTT(1-17) peptide determined in
the present work provides a structural explanation
for this inhibition as the binding of the C4 scFv to the
peptide segment would sterically hinder the self-
association process of the HTT(1-17) segment.
Furthermore, C4 scFv increases the solubility of the
peptide by interacting with the residues Leu4HTT,
Leu8HTT and Phe11HTT, which adopt helical confor-
mations resulting in the formation of a hydrophobic
surface. This surface is thus shielded from the solvent
and protected from self-association with other HTT
fragments, as well as from interactions with cellularmembranes that have been suggested to be an
important factor in the nucleation of toxic mHTT
aggregates [18,32–35].
The binding of C4 scFv to HTT(1-17) in solution
The intrabody C4 scFv was obtained from a
human synthetic scFv library, and it was selected
against a C-terminally biotinylated HTT(1-17) pep-
tide [24]. The conformation of the HTT(1-17) peptide
that is recognized by the C4 scFv is therefore
expected to be one that is highly populated, or
readily accessible, in solution as antibodies or
antibody fragments do not generally bind to high-
energy states [36]. Indeed, in recent studies includ-
ing molecular dynamics simulations it was predicted
that structures of HTT(1-17) in which residues 3–11
adopt α-helical conformations and residues 12–17
extended and disordered conformations are highly
populated within the ensemble of solution struc-
tures [37]. The propensity of the HTT(1-17) peptide
to form α-helical conformations has been confirmed
by a range of biophysical studies, including CD,
Fourier transform infrared (FTIR) spectroscopy and
NMR spectroscopy, which show that the peptide is
predominantly disordered in dilute solutions but that
it acquires helical structure in concentrated solutions
[38]. Similar increases in helical content can be
induced by the presence of organic solvents, such as
trifluoroethanol [34], or through interactions with other
partners, such as detergents or membranes [18,34], or
proteins, including molecular chaperones [7,39–41].
The major involvement of the α-helical region of
HTT(1-17) in binding to a protein molecule is also
revealed from the crystal structure of this peptide
including the first residue of the polyQ domain of
HTT, with a different intrabody, VL12.3 [42]. The
binding site of this intrabody to HTT, however,
involves residues 5HTT–18HTT and so includes the
first residue of the polyQ tract of HTT-exon1. In
addition, all the residues of the peptide involved in
Fig. 5. 15N-1H Heteronuclear sin-
gle quantum correlation spectroscopy
measurements of uniformly labeled
C4 scFv in its free form and bound to
HTT(1-17), in solution. (a) Overlay of
15N-1H HSQC NMR spectra of
uniformly 15N-labeled C4 scFv (red)
and of uniformly 15N-labeled C4 scFv
in the presence of 2 equivalents of
unlabeled HTT(1-17) peptide (blue).
Resonances of residues that show
significant chemical shift differences
between the free and the bound
states are connected with a black
line and resonances of residues that
are not detectable in the free spec-
trum but become detectable in the
bound spectrum are labeled in red
boxes. (b) Bar graph representation of
the chemical shift changes in the free
and bound states for each of the
assigned residues of C4 scFv (the
change in chemical shift is defined as
[0.04 × (δ15Nfree − δ15Nbound)2 +
(δ1Hfree − δ1Hbound)2]1/2 [66]). Reso-
nances of the residues that could not
be assigned in the free spectrum but
that did become detectable in the
bound state are drawn as red bars
with an arbitrary y value of 0.8. (c)
Values of the bar graph in (b) mapped
on to the structure of C4 scFv in
complex with the peptide HTT(1-17);
the magnitudes of the shifts of C4
scFv residues are colorcoded going
from dark blue (insignificant shift,
~ 0 ppm) to red (major shif t ,
N0.7 ppm) according to the colorcod-
ing on the spectrum bar at the bottom
of the panel. The residues indicated in
red in (a) and (b) are also colored red
on the structure andare labeled in red.
The residues Y161 and F220, which
show significant chemical shift pertur-
bations and which are in contact with
F17HTT in the crystal structure, are
also labeled. Unassigned residues in
both spectra are colored gray, and the
peptide is represented in ribbon for-
mat and colored cyan. The peptide
residues 15HTT–17HTT from the sec-
ond C4 scFv:HTT(1-17) complex that
make contact in the asymmetric are
shown as a green ribbon. The side
chain of Phe17HTT in both peptides is
also shown and labeled.
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(Fig. S4), most probably because a large region of
exposed hydrophobic surface allows the burial in the
complex of the hydrophobic side chains of Leu7HTT,
Phe11HTT, Leu14HTT and Phe17HTT, and may
stabilize Gln18HTT in a helical conformation.The origin and relevance of the dimeric
arrangement of C4 scFv:HTT(1-17)
complexes observed in the crystal structure
The remarkable dimeric C4 scFv:HTT(1-17) com-
plex that is observed in the crystal structure (Fig. 2)
could not be detected in solution by analytical
centrifugation, gel filtration or mass spectrometric
techniques (Fig. S2). The interactions involved in the
formation of this complex are, however, extensive
and are predicted to be highly relevant by PISA
analysis (Table 2).
A question that emerges, therefore, is whether the
intermolecular interaction found in the crystal is a
newly formed interface during the crystallization
process or if it is the result of domain swapping
[43–45]. In the latter case, structurally and energet-
ically equivalent “intra”-molecular interactions are
exchanged with “inter”-molecular ones. This would
imply that residues 15HTT–17HTT fold back onto
residues 11HTT–13HTT, in solution, generating favor-
able interactions within the same peptide molecule
and interactions with the C4 scFv and possibly
including an interaction of the side chain of Phe17HTT
in a hydrophobic pocket formed by the aromatic side
chains of Phe220VL and Tyr161VL and the side
chain of Arg100VH (Fig. 4b). In our NMR analysis,
small chemical shift perturbations for residues of C4
scFv that are in contact with residues 15HTT–17HTT
in the crystal structure that might be indicative of an
interaction were observed (Fig. 5). Preliminary
analysis of this interaction using isothermal calo-
rimetry and truncated HTT(1-17) peptides shows,
however, that this region contributes only moder-
ately to the binding energy (Fig. S3). The elucidation
of the exact roles of these residues in the binding
interact ion wil l , therefore, require further
investigation.
Nevertheless, the formation of β-sheet structure
within the C4 scFv:HTT(1-17) complexes, which
primarily involves residues 11–17 of the HTT
peptide, is a very interesting observation. It seems
that, in this particular conformation of the peptide
bound to the C4 scFv, residues 3HTT–11HTT form an
amphipathic helix and that residues 12HTT–17HTT
form an extended (β-sheet) structure, which seem to
be stabilized by backbone hydrogen-bonding inter-
actions with residues of the C4 scFv on either side of
the antiparallel β-sheet formed by the residues
12HTT–17HTT (Fig. 4a). It is therefore possible to
speculate about the relevance of this conformation inthe mechanism of enhanced mHTT fibril formation
by HTT(1-17) in vitro and in vivo as the formation of
this structural feature, if it were not blocked from
further growth due to the presence of C4 scFv, might
lead to a dramatically enhanced propensity of HTT to
form β-sheet fibrillar structures. Interestingly, it has
been shown from solid-state NMR measurements
that this exact conformation of HTT(1-17), adopting a
partly helical (residues 4–11) and a partly extended
or β-sheet conformation (residues 12–17), is highly
populated in mHTT fibrils [22]. The dimeric structure
of C4 scFv:HTT(1-17) complex might therefore
provide a clue as to the key initial events in HTT
fibril formation.Significance for an antibody-bound therapeutic
strategy targeting HD
Antibody technologies have proved to be capable
of generating powerful therapeutic agents for a wide
variety of diseases ranging from cancer to multiple
sclerosis [46,47]. Increasing attention has recently
been given to intrabodies [48,49], antibody frag-
ments that are recombinantly engineered to be
expressed in cells and that have exquisite specificity
combined with high affinity, stability and solubility.
Intrabodies have been shown to have significant
potential for acting as inhibitors of events associated
with protein misfolding and aggregation diseases
[50–55]. For HD, several recombinant antibodies
and intrabodies have been raised against translation
products of HTT exon1, and it is now apparent that
the ability of anti-HTT intrabodies to modulate
aggregation and its associated neurotoxicity de-
pends strongly on the epitope of HTT toward which
they are directed [48].
The key involvement of the HTT(1-17) region in the
pathogenic deposition of mHTT aggregates, as well
as its inhibition by molecular chaperones that can
bind HTT(1-17) [7,41,56], makes it a very attractive
target for the development of intrabodies designed to
suppress mHTT aggregation. At the present time,
two intrabodies that bind to this region, VL12.3 [42]
and C4 scFv [24], have been reported, and we have
described the crystal structure of the latter when
complexed with HTT(1-17) in the present manu-
script. Both antibody species have been found to
bind to the N-terminal residues of HTT and also to
reduce mHTT-induced aggregation and toxicity very
potently both in vitro and in situ, while not altering
significantly the turnover of mHTT [24,25]. These
intrabodies differ in the residues of HTT(1-17) with
which they make contact and they have similar
binding affinities, 44 nM (VL12.3) [57] versus 50 nM
(C4 scFv) (Fig. S3). The epitope for VL12.3 is
located further from the N-terminus of HTT(1-17) and
appears to block cytoplasmic retention of
mHTT-exon1 leading to much higher levels of an
2175Structure of a Single-Chain Fv Bound to Huntingtinantigen–antibody complex in the nucleus [58,59]
than are found for C4 scFv. The nucleus is known to
be a major site of mHTT pathogenesis, and retention
in the nucleus is likely to be at least partly
responsible for the lack of long-term in vivo efficacy
of this construct.
It has also been shown that binding of this scFv
intrabody to full-length HTT is very weak, possibly
due to a different conformation of the epitope when
embedded in the full-length protein [25]. As a
consequence of the latter effects, the presence of
the intrabody in the cell is likely to have only minimal
effects on the normal function of full-length HTT. To
further enhance therapeutic efficacy of C4 scFv,
we greatly increased degradation of toxic mHTT
fragments by engineering the C4 scFv to include
a proteasome degradation tag [23]. Thus, the
combined properties of the C4 scFv, notably its
cytoplasmic localization, its specificity for toxic HTT
fragments and its amenability toward protein engi-
neering, suggest that this intrabody could be a
valuable lead in the quest for an effective therapeutic
strategy for combating HD.Materials and Methods
Cloning, expression and purification of C4 scFv
The gene for C4 scFv was synthesized (GenScript, New
Jersey, USA) on the basis of the amino acid sequence of
the protein (GenBank ID: ACA53373.1) and optimized for
E. coli codon usage and cloned, expressed and purified
as described hereafter. After the removal of the PstI
restriction site at 628 bp, the gene for C4 scFv with the
addition of a C-terminal tag containing six consecutive
histidines to enhance purification was subcloned using
PstI and EcoRI into the vector pHEN6 for expression in the
periplasm of E. coli cells. Subsequently, CaCl2-competent
WK6 E. coli cells were transformed with the recombinant
DNA to obtain expression clones of the C4 scFv product.
Isotopically naturally abundant, as well as 15N and 13C
isotopically enriched, samples of C4 scFv were produced
and purified according to previously reported protocols for
periplasmic expression of single-domain antibodies [53].In vitro aggregation experiments
In vitro aggregation studies of the exon1 of the huntingtin
protein carrying a stretch of 46 glutamine (HTT-Ex1-Q46)
were performed using HTT-Ex1-Q46 fused to MBP
(MBP-HTT-Ex1-Q46), purified as described earlier [26].
To induce amyloid formation by HTT-Ex1-Q46, we
removed the MBP solubilization tag by incubation for 6 h
with the TEV protease, which recognizes a specific
cleavage site within the linker sequence between the
MBP and HTT(1-17). At this 6-h timepoint, the MBP tag
was fully removed, and the amount of soluble
HTT-Ex1-Q46 was used as the 100% solubility reference.
To assess the effect of different compounds on theaggregation of HTT-Ex1-Q46, we added these com-
pounds after 6 h of initial TEV digestion, and the mixture
was further incubated for 70 additional hours (total time,
76 h).
The detailed protocol was as follows:. 5 μl of
MBP-HTT-Ex1-Q46 [7.6 μM, conserved at −20 °C in
5 mM Tris, 25 mM NaCl, 25 mM KCl and 50% glycerol
(pH 7.3)], 1 μl of TEV buffer [10× stock: 500 mMTris, 5 mM
EDTA and 10 mM DTT (pH 8)], 1 μl of acTEV (stock: 10 U/
μl; Invitrogen) and 1 μl of phosphate buffer (50 mM, pH 7)
were mixed for 6 h at room temperature (~25 °C). After 6 h
of digestion, 2 μl of either phosphate buffer, C4 scFv, QBP1
[60] or a non-relevant scFvR19 raised against gankyrin [28]
was added and further incubated for different times
(between 0 min for the point 6 h and 70 h for the point
76 h). Final concentrations upon incubation were as follows:
MBP-HTT-Ex1-Q46 (3.8 μM), QBP1 (100 μM), C4 scFv
(11 μM) and scFvR19 (11 μM). After incubation, samples
were centrifuged (22,000g, 5 min, 4 °C) and 9.5 μl super-
natant was mixed with 9.5 μl Laemmli loading dye and
SDS-PAGE running buffer. We loaded 9 μl or 3 μl of each
sampleon several SDS-PAGE (16%) gels that, respectively,
were either stained with Coomassie blue after electropho-
resis or transferred onto nitrocellulose membranes for
Western blotting with the primary 1C2 polyQ-specific
antibody [61] and a secondary GAM-peroxidase antibody.
Supersignal West Pico (Thermo Scientific, Illkirch, France)
was added for revelation. The chemiluminescent signal was
recorded on a Fusion (Fx7) image acquisition system, and
the signal intensity was quantified using the included Bio1d
software (Vilber Lourmat, Marne-La-Vallée, France). Note
that QBP1, C4 scFv, scFvR19 and TEV are not detected by
Western blotting using the 1C2 and GAM-peroxidase
antibodies.
Crystallization, X-ray data collection and
structure solution
The C4 scFv antibody at 15 mg/ml was mixed with a
5-fold excess of a solubilized freeze-dried HTT(1-17)
peptide in 20 mM Hepes buffer at pH 7.4 containing
150 mM NaCl. Crystals were grown by hanging-drop
vapor diffusion in 0.2 M ammonium sulfate, 25% polyeth-
ylene glycol 4000 and 0.1 M sodium acetate buffer at
pH 4.6.
X-ray diffraction data at 100 K of frozen C4 scFv:
HTT(1-17) crystals were collected to a resolution of 3.1 Å
on a Microstar microfocus rotating anode X-ray generator
Icarus: X8 Proteum (Bruker AXS, Coventry, UK) equipped
with a Platinum 135 CCD detector. The data were
processed using Proteum 2 software (Bruker AXS) and
the phase information associated with the structure factors
was found by using the program Phaser [62]. The VL and
VH domains of the crystal structure of the anti-SARS spike
protein receptor domain scFv, 80R (2ghw) [63], after
deletion of the coordinates for the residues of the
hypervariable loop regions, were used as search models
for the VL and the VH domains of the C4 scFv,
respectively. Synchrotron X-ray diffraction data
were recorded using the Proxima 1 beamline at the
European Synchrotron Radiation Facility at SOLEIL in
Paris, France. Data were collected to a resolution of 2.5 Å.
Rebuilding of the hypervariable loops and the building
of the peptide antigen structure was performed both
2176 Structure of a Single-Chain Fv Bound to Huntingtinmanually and automatically using the program Auto-build
in Phenix [64]. Phenix was also used to refine the
structure. Data collection and refinement statistics are
listed in Table 1.Structural analysis
The programs Contact, HBplus and Areaimol (Collabora-
tive Computational Project Number 4) were used to analyze
the structural and chemical features of the complex, namely,
inter-atomic distances, hydrogen bonds and changes in
solvent-accessible surface area upon complex formation.
The Web server PISA† was used to score the biological
significance of the various interfaces formed by the protein
chains within the crystal [30]. Figures were prepared using
the program PyMOL‡.NMR spectroscopy
Standard 15N-1H HSQC experiments were carried out at
a 1H frequency of 700 MHz. Spectra of 15N-labeled C4
scFv were recorded free or in the presence of 1.2 molar
equivalents of unlabeled HTT(1-17) peptide (Genemed
Synthesis Inc., New York, USA). All experiments were
recorded in 10 mM phosphate and 150 mM NaCl at
pH 5.9 and at 310 K. For backbone assignments of C4
scFv in its unbound state, standard triple resonance
experiments [HNCA, CBCA(CO)NH, HNCACB, HNCO
and HN(Ca)CO spectra] were recorded at 310 K using a
Bruker Avance 700-MHz spectrometer equipped with a
cryogenic triple resonance probe (Bruker, Coventry, UK).
The chemical shifts of individual spin systems (HN, N, Ca,
Cb and CO) were collected manually and the backbone
resonance assignments were achieved iteratively through
a combination of computer-aided automated assignment
procedure using the program Mars [65]. HNCA and
CBCA(CO)NH spectra were recorded to determine the
assignments of the resonances of the N, H, Ca and Cb
atoms of the residues of C4 scFv in the presence of an
equimolar amount of unlabeled HTT(1-17) peptide.Accession numbers
Coordinates have been deposited in the Protein Data
Bank under ID code 4RAV.Acknowledgements
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